Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.

IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM BMJ Open Diabetes Research & Care Pub Date : 2024-05-30 DOI:10.1136/bmjdrc-2024-004115
Kaori Kitaoka, Yuichiro Yano, Hajime Nagasu, Hiroshi Kanegae, Noriharu Chishima, Hiroki Akiyama, Kouichi Tamura, Naoki Kashihara
{"title":"Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.","authors":"Kaori Kitaoka, Yuichiro Yano, Hajime Nagasu, Hiroshi Kanegae, Noriharu Chishima, Hiroki Akiyama, Kouichi Tamura, Naoki Kashihara","doi":"10.1136/bmjdrc-2024-004115","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We compared the kidney outcomes between patients with diabetic kidney disease (DKD) aged ≥75 years initiating sodium-glucose cotransporter 2 (SGLT2) inhibitors versus other glucose-lowering drugs, additionally presenting with or without proteinuria.</p><p><strong>Research design and methods: </strong>Using the Japan Chronic Kidney Disease Database, we developed propensity scores, implementing a 1:1 matching protocol. The primary outcome included the decline rate in estimated glomerular filtration rate (eGFR), and secondary outcomes incorporated a composite of a 40% reduction in eGFR or progression to end-stage kidney disease.</p><p><strong>Results: </strong>At baseline, the mean age at initiation of SGLT2 inhibitors (n=348) or other glucose-lowering medications (n=348) was 77.7 years. The mean eGFR was 59.3 mL/min/1.73m<sup>2</sup> and proteinuria was 230 (33.0%) patients. Throughout the follow-up period, the mean annual rate of eGFR change was -0.80 mL/min/1.73 m<sup>2</sup>/year (95% CI -1.05 to -0.54) among SGLT2 inhibitors group and -1.78 mL/min/1.73 m<sup>2</sup>/year (95% CI -2.08 to -1.49) in other glucose-lowering drugs group (difference in the rate of eGFR decline between the groups was 0.99 mL/min/1.73 m<sup>2</sup>/year (95% CI 0.5 to 1.38)), favoring SGLT2 inhibitors (p<0.001). Composite renal outcomes were observed 38 in the SGLT2 inhibitors group and 57 in the other glucose-lowering medications group (HR 0.64, 95% CI 0.42 to 0.97). There was no evidence of an interaction between SGLT2 inhibitors initiation and proteinuria.</p><p><strong>Conclusions: </strong>The benefits of SGLT2 inhibitors on renal outcomes are also applicable to older patients with DKD aged≥75 years.</p>","PeriodicalId":9151,"journal":{"name":"BMJ Open Diabetes Research & Care","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141184/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Diabetes Research & Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjdrc-2024-004115","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We compared the kidney outcomes between patients with diabetic kidney disease (DKD) aged ≥75 years initiating sodium-glucose cotransporter 2 (SGLT2) inhibitors versus other glucose-lowering drugs, additionally presenting with or without proteinuria.

Research design and methods: Using the Japan Chronic Kidney Disease Database, we developed propensity scores, implementing a 1:1 matching protocol. The primary outcome included the decline rate in estimated glomerular filtration rate (eGFR), and secondary outcomes incorporated a composite of a 40% reduction in eGFR or progression to end-stage kidney disease.

Results: At baseline, the mean age at initiation of SGLT2 inhibitors (n=348) or other glucose-lowering medications (n=348) was 77.7 years. The mean eGFR was 59.3 mL/min/1.73m2 and proteinuria was 230 (33.0%) patients. Throughout the follow-up period, the mean annual rate of eGFR change was -0.80 mL/min/1.73 m2/year (95% CI -1.05 to -0.54) among SGLT2 inhibitors group and -1.78 mL/min/1.73 m2/year (95% CI -2.08 to -1.49) in other glucose-lowering drugs group (difference in the rate of eGFR decline between the groups was 0.99 mL/min/1.73 m2/year (95% CI 0.5 to 1.38)), favoring SGLT2 inhibitors (p<0.001). Composite renal outcomes were observed 38 in the SGLT2 inhibitors group and 57 in the other glucose-lowering medications group (HR 0.64, 95% CI 0.42 to 0.97). There was no evidence of an interaction between SGLT2 inhibitors initiation and proteinuria.

Conclusions: The benefits of SGLT2 inhibitors on renal outcomes are also applicable to older patients with DKD aged≥75 years.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在实际临床实践中,SGLT2 抑制剂对老年糖尿病肾病患者的肾脏疗效:日本慢性肾病数据库试验。
简介我们比较了年龄≥75岁的糖尿病肾病(DKD)患者开始服用钠-葡萄糖共转运体2(SGLT2)抑制剂与其他降糖药物,同时伴有或不伴有蛋白尿时的肾脏预后:利用日本慢性肾脏病数据库,我们制定了倾向评分,并实施了 1:1 匹配方案。主要结果包括估计肾小球滤过率(eGFR)的下降率,次要结果包括eGFR下降40%或进展至终末期肾病的综合结果:基线时,开始服用 SGLT2 抑制剂(348 人)或其他降糖药物(348 人)的平均年龄为 77.7 岁。平均 eGFR 为 59.3 毫升/分钟/1.73 平方米,蛋白尿患者为 230 人(33.0%)。在整个随访期间,SGLT2 抑制剂组患者的 eGFR 平均年变化率为-0.80 mL/min/1.73 m2/年(95% CI -1.05 至-0.54),其他抑制剂组患者的 eGFR 平均年变化率为-1.78 mL/min/1.73 m2/年(95% CI -2.08 至-1.49)。08至-1.49)(组间eGFR下降率差异为0.99 mL/min/1.73 m2/年(95% CI 0.5至1.38)),SGLT2抑制剂更有利(P结论:SGLT2抑制剂对肾脏预后的益处也适用于年龄≥75岁的老年DKD患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
9.30
自引率
2.40%
发文量
123
审稿时长
18 weeks
期刊介绍: BMJ Open Diabetes Research & Care is an open access journal committed to publishing high-quality, basic and clinical research articles regarding type 1 and type 2 diabetes, and associated complications. Only original content will be accepted, and submissions are subject to rigorous peer review to ensure the publication of high-quality — and evidence-based — original research articles.
期刊最新文献
Effect of weight-maintaining ketogenic diet on glycemic control and insulin sensitivity in obese T2D subjects. National health and economic impact of a lifestyle program to prevent type 2 diabetes mellitus in Germany: a simulation study. Ethnic-specific oral glucose tolerance (OGTT) phenotypes in women with hyperglycemia in pregnancy. Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA. Applying machine learning approaches for predicting obesity risk using US health administrative claims database.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1